
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax is poised for success with their promising drug Obefazimod, which has the potential to become a first-line therapy for ulcerative colitis due to its strong results and potential for combination treatments. However, the company must address concerns about potential side effects and secure partnerships for development and commercialization, while also expanding into other indications to generate revenue and mitigate intellectual property risks. Despite these challenges, Abivax's potential success in the UC and CD market positions it as a strong investment opportunity.
Bears say
Abivax is currently facing a challenging landscape as it competes with established companies in the IBD market and has yet to successfully bring a drug to market. While its drug candidate, obefazimod, shows potential, there are significant safety concerns that may hinder its success. Additionally, the company's financials are not yet strong enough to support its ambitious R&D plans.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares